Literature DB >> 21497562

American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.

Steven J Frank, V Elayne Arterbery, I-Chow Joe Hsu, May Abdel-Wahab, Jay P Ciezki, Noah M Hahn, James Lloyd Mohler, Brian J Moran, Seth A Rosenthal, Carl J Rossi, Yoshiya Yamada, Gregory Merrick.   

Abstract

PURPOSE: Permanent prostate brachytherapy has emerged as a standard of care treatment for approximately 50,000 men annually who present with clinically localized prostate cancer. The purpose of this review was to provide clarification on the appropriateness criteria and management considerations for the treatment of prostate cancer with permanent prostate brachytherapy.
METHODS: Panel members with expertise on prostate cancer were assembled and provided several clinical scenarios for consensus treatment and management guidelines. Prostate cancer patient vignettes were presented along with specific management recommendations based on an extensive review of the modern brachytherapy literature. The brachytherapy topic development and review consists of two parts which require extensive participation by the expert panel. The American College of Radiology (ACR) Appropriateness Criteria (AC) are derived from a multidisciplinary panel of experts from both the academic and private practice settings. The first activity is a review of the current literature with development of an evidence table, referenced narrative, and ratings table of treatments. The second activity is the consensus-building process using a modified Delphi technique via an anonymous voting process.
RESULTS: Most brachytherapy series have demonstrated favorable morbidity profiles and durable biochemical control rates for patients with low-, intermediate-, and high-risk features. However, as brachytherapy followups have matured, it has become increasingly apparent that efficacy and morbidity are highly dependent on implant quality.
CONCLUSION: Continued attempts to refine patient selection, brachytherapy treatment planning philosophy, technique, and postimplant management should result in further improvements in biochemical outcome and decreased brachytherapy-related morbidity.
Copyright © 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21497562     DOI: 10.1016/j.brachy.2011.01.014

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  7 in total

Review 1.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

Review 2.  American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Authors:  M Keyes; G Merrick; S J Frank; P Grimm; M J Zelefsky
Journal:  Brachytherapy       Date:  2017-01-16       Impact factor: 2.362

3.  Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy.

Authors:  Thomas J Pugh; Steven J Frank; Mary Achim; Deborah A Kuban; Andrew K Lee; Karen E Hoffman; Sean E McGuire; David A Swanson; Rajat Kudchadker; John W Davis
Journal:  Brachytherapy       Date:  2012-06-05       Impact factor: 2.362

4.  Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging.

Authors:  Geoffrey V Martin; Thomas J Pugh; Usama Mahmood; Rajat J Kudchadker; Jihong Wang; Teresa L Bruno; Tharakeswara Bathala; Steven J Frank
Journal:  Brachytherapy       Date:  2017-03-09       Impact factor: 2.362

5.  Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.

Authors:  Jason A Efstathiou; Deborah S Nassif; Todd R McNutt; C Bob Bogardus; Walter Bosch; Jeffrey Carlin; Ronald C Chen; Henry Chou; Dave Eggert; Benedick A Fraass; Joel Goldwein; Karen E Hoffman; Ken Hotz; Margie Hunt; Marc Kessler; Colleen A F Lawton; Charles Mayo; Jeff M Michalski; Sasa Mutic; Louis Potters; Christopher M Rose; Howard M Sandler; Gregory Sharp; Wolfgang Tomé; Phuoc T Tran; Terry Wall; Anthony L Zietman; Peter E Gabriel; Justin E Bekelman
Journal:  J Oncol Pract       Date:  2013-05       Impact factor: 3.840

6.  Progressive transition from pre-planned to intraoperative optimizing seed implant: post implementation analysis.

Authors:  Hsiang-Chi Kuo; William Bodner; Ravindra Yaparpalvi; Chandan Guha; Bhupendra M Tolia; Keyur J Mehta; Dennis Mah; Shalom Kalnicki
Journal:  J Contemp Brachytherapy       Date:  2012-03-30

7.  KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.

Authors:  Carlo Barone; Carmine Pinto; Nicola Normanno; Lorenzo Capussotti; Francesco Cognetti; Alfredo Falcone; Lorenzo Mantovani
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.